SLC7A5 and plasma cell myeloma: Additionally, SLC7A5 serves as a pivotal regulatory factor in the treatment of various cancers, including multiple myeloma, breast cancer, and gastric cancer, and represents a potential therapeutic target for overcoming patient resistance (38–40).